1. Home
  2. FFIC vs LCTX Comparison

FFIC vs LCTX Comparison

Compare FFIC & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FFIC
  • LCTX
  • Stock Information
  • Founded
  • FFIC 1929
  • LCTX 1990
  • Country
  • FFIC United States
  • LCTX United States
  • Employees
  • FFIC N/A
  • LCTX 77
  • Industry
  • FFIC Major Banks
  • LCTX Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • FFIC Finance
  • LCTX Health Care
  • Exchange
  • FFIC Nasdaq
  • LCTX Nasdaq
  • Market Cap
  • FFIC 446.6M
  • LCTX 405.4M
  • IPO Year
  • FFIC 1995
  • LCTX N/A
  • Fundamental
  • Price
  • FFIC $15.38
  • LCTX $1.83
  • Analyst Decision
  • FFIC
  • LCTX Strong Buy
  • Analyst Count
  • FFIC 0
  • LCTX 4
  • Target Price
  • FFIC N/A
  • LCTX $4.25
  • AVG Volume (30 Days)
  • FFIC 294.9K
  • LCTX 1.9M
  • Earning Date
  • FFIC 10-29-2025
  • LCTX 11-06-2025
  • Dividend Yield
  • FFIC 5.70%
  • LCTX N/A
  • EPS Growth
  • FFIC N/A
  • LCTX N/A
  • EPS
  • FFIC N/A
  • LCTX N/A
  • Revenue
  • FFIC $143,853,000.00
  • LCTX $10,816,000.00
  • Revenue This Year
  • FFIC $113.60
  • LCTX N/A
  • Revenue Next Year
  • FFIC $7.42
  • LCTX $176.00
  • P/E Ratio
  • FFIC N/A
  • LCTX N/A
  • Revenue Growth
  • FFIC N/A
  • LCTX 24.05
  • 52 Week Low
  • FFIC $10.65
  • LCTX $0.37
  • 52 Week High
  • FFIC $18.59
  • LCTX $2.09
  • Technical
  • Relative Strength Index (RSI)
  • FFIC 71.05
  • LCTX 57.56
  • Support Level
  • FFIC $12.75
  • LCTX $1.53
  • Resistance Level
  • FFIC $14.29
  • LCTX $2.09
  • Average True Range (ATR)
  • FFIC 0.43
  • LCTX 0.13
  • MACD
  • FFIC 0.23
  • LCTX -0.01
  • Stochastic Oscillator
  • FFIC 92.20
  • LCTX 52.68

About FFIC Flushing Financial Corporation

Flushing Financial Corp operates as a bank holding company, which is engaged in the provision of banking and financial services. It provides Personal, Business, lending, Government banking, and Card services. Its principal business is attracting retail deposits from the general public and investing those deposits together with funds generated from ongoing operations and borrowings, in originations and purchases of multi-family residential properties, commercial business loans, commercial real estate mortgage loans, construction loans, small business administration loans, and other small business loans.

About LCTX Lineage Cell Therapeutics Inc.

Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline is based on two platform technologies including cell replacement and cell/drug delivery. Lineage Cell's product candidate is OpRegen, a retinal pigment epithelium transplant therapy for the treatment of dry age-related macular degeneration, OPC1, an oligodendrocyte progenitor cell therapy for acute spinal cord injuries, and VAC2, allogeneic cancer immunotherapy of antigen-presenting dendritic cells for non-small cell lung cancer, ANP1, an allogeneic auditory neuron progenitor cells transplant for hearing loss, and PNC1, an allogeneic photoreceptor cell transplant for vision loss.

Share on Social Networks: